Gynecological Cancer Clinical Trials

Trials are listed from Phase 1 to Phase 3, alphabetically.  Please click on the name of the Lead Clinical Research Coordinator (CRC) to request more information about each trial.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


STRO-002-GM1 NCT03748186 A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancer S. Ghamande Ashlyn Stevenson Ovarian and Endometrial Cancers I
TESARO 4010-01-001   NCT0275284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Ashlyn Stevenson Advanced solid tumors I
1951-CL-0101 NCT03799003 A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors S. Ghamande Katie Dorr Advanced solid tumors Ib
MS200647-0046 NCT04551950 Safety Study of Bintrafusp alfa in Combination with Other Anti-cancer Therapies in Participants with Locally Advanced or Advanced Cervical Cancer Protocol S. Ghamande Kristen Culpepper Cervical Cancer Ib
MORAb-202-G000-201 NCT04300556 A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types S. Ghamande Kristen Culpepper Endometrial, Ovarian, or Peritoneal Cancer I/II 
EP0057-201 NCT04669002 A Phase 2 Study to Evaluate the Safety and Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 Platinum Resistant Disease and are PARP Inhibitor Naïve; Cohort 2   Had at Least 2 Prior Lines of Therapy Which Must Include at Least 1 Line of Platinum-Based Chemotherapy Followed by PARP Inhibitor Maintenance S. Ghamande Brooke Duran Ovarian Cancer II
GOG-3028/C-750-01  NCT03894215 A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS S. Ghamande Melissa James Cervical Cancer II
LION C-145-04  NCT03108495 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma S. Ghamande Katie Dorr Cervical Cancer II
NRG-GY006 NCT02466971 
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer S. Ghamande  Melissa James Uterine Cervical or Vaginal Cancer II
NRG-GY017  NCT03738228 Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer S. Ghamande Melissa James Cervical Cancer II
SGNTV-002  NCT03657043 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen S. Ghamande Donna Wheatley Ovarian Cancer II
NRG-GY009 NCT02839707 A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer S. Ghamande Melissa James Ovarian Cancer II/III
GOG-3055/KCP-330-024 NCT03555422 A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer Protocol S. Ghamande Jebbiden Small Endometrial III
GOG-3031/4010-03-001 NCT03981796 A Phase 3, Randomized, Double-blind, Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer S. Ghamande Kristen Culpepper Endometrial III
GOG-3057/SGNTV-003 NCT04697628 A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer S. Ghamande Katie Dorr Cervical III
GOG-3059/AVB500-OC-004 NCT04729608 A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer S. Ghamande Katie Dorr Ovarian III